GlassScriptPhysician profile
Dianna L Keeling
NPI 1609115237
$2,496.23
in general payments reported to CMS, 2019-2025
34 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $781 · 2023: $311 · 2024: $308 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.57 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $378.71 | 2021-2024 | Mounjaro, Trulicity |
| Astellas Pharma US INC | $258.57 | 2021-2023 | Xtandi |
| Amgen INC. | $244.76 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $230.13 | 2021-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Merck Sharp & Dohme LLC | $157.62 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $99.33 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tersera Therapeutics LLC | $98.48 | 2021-2022 | |
| Braeburn INC. | $91.96 | 2023-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.09 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $89.17 | 2024-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $85.94 | 2021 | |
| Exact Sciences Corporation | $78.47 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $58.97 | 2021-2022 | |
| Lundbeck LLC | $53.01 | 2023-2025 | Rexulti |
| Eisai INC. | $49.69 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $41.53 | 2021-2022 | |
| Genzyme Corporation | $40.06 | 2021 | |
| Genentech USA, INC. | $35.74 | 2021-2022 | |
| Incyte Corporation | $34.86 | 2021-2022 | |
| Celgene Corporation | $34.78 | 2022 | |
| Medtronic, INC. | $25.04 | 2022 | |
| Grifols USA, LLC | $24.91 | 2023 | Prolastin-C Liquid |
| Organon LLC | $22.04 | 2022 | |
| Progenics Pharmaceuticals, INC. | $21.99 | 2022 | |
| Daiichi Sankyo INC. | $18.32 | 2021 | |
| Abbvie INC. | $16.42 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.13 | 2024 | Gvoke Hypopen |
| Janssen Biotech, INC. | $15.21 | 2021 | |
| Tg Therapeutics, INC. | $14.92 | 2021 | |
| Array Biopharma INC | $14.39 | 2021 | |
| Axsome Therapeutics, INC. | $14.28 | 2025 | Auvelity |
| Ipsen Biopharmaceuticals, INC | $14.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.12 | 2022 | |
| Aveo Pharmaceuticals, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianna Keeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.